Sevelamer and extension studies [3]

Kidney International

Volumn 72, Issue 2, 2007, Pages 225-226

  McFarlane, P A ^a  

^a UNIVERSITY OF TORONTO   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

CALCIUM PHOSPHATE; PHOSPHATE BINDING AGENT; SEVELAMER;

CLINICAL RESEARCH; DIALYSIS; HAZARD ASSESSMENT; LETTER; MORTALITY; PRIORITY JOURNAL;

CLINICAL PROTOCOLS; HUMANS; POLYAMINES; RANDOMIZED CONTROLLED TRIALS; RENAL DIALYSIS; SURVIVAL ANALYSIS;

EID: 34447511001     PISSN: 00852538     EISSN: 15231755     Source Type: Journal    
DOI: 10.1038/sj.ki.5002314     Document Type: Letter

References (5)

1. Block GA, Raggi P, Bellasi A et al. Mortality effect of coronary calcification and phosphate binder choice in incident hemodialysis patients. Kidney Int 2007; 71: 438-441.
2. Bosch J, Lonn E, Pogue J et al. Long-term effects of ramipril on cardiovascular events and on diabetes: results of the HOPE study extension. Circulation 2005; 112: 1339-1346.
3. Hall AS, Murray GD, Ball SG. Follow-up study of patients randomly allocated ramipril or placebo for heart failure after acute myocardial infarction: AIRE Extension (AIREX) Study. Acute Infarction Ramipril Efficacy. Lancet 1997; 349: 1493-1497.
4. Staessen JA, Thijisq L, Fagard R et al. Effects of immediate versus delayed antihypertensive therapy on outcome in the Systolic Hypertension in Europe Trial. J Hypertens 2004; 22: 847-857.
5. Block GA, Spiegel DM, Ehrlich J et al. Effects of sevelamer and calcium on coronary artery calcification in patients new to hemodialysis. Kidney Int 2005; 68: 1815-1824.